Copanlisib + Rituximab
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Marginal Zone Lymphoma
Conditions
Marginal Zone Lymphoma
Trial Timeline
Dec 15, 2019 → Dec 31, 2027
NCT ID
NCT03474744About Copanlisib + Rituximab
Copanlisib + Rituximab is a phase 2 stage product being developed by Celltrion for Marginal Zone Lymphoma. The current trial status is active. This product is registered under clinical trial identifier NCT03474744. Target conditions include Marginal Zone Lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03474744 | Phase 2 | Active |
Competing Products
10 competing products in Marginal Zone Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Rituximab + Pembrolizumab | Celltrion | Phase 2 | 52 |
| Pirtobrutinib + Rituximab | Eli Lilly | Phase 2 | 52 |
| Epcoritamab | AbbVie | Phase 2 | 52 |
| Rituximab + Venetoclax | AbbVie | Phase 2 | 52 |
| VAY736 + lenalidomide | Novartis | Phase 1 | 33 |
| PI3K inhibitor BKM120 + rituximab | Novartis | Phase 1 | 33 |
| Obinutuzumab | Roche | Phase 2 | 52 |
| Umbralisib | TG Therapeutics | Phase 2 | 49 |
| HMPL-689 | HUTCHMED | Phase 2 | 47 |
| Loncastuximab tesirine 150 µg/Kg + Loncastuximab tesirine 75µg/Kg | ADC Therapeutics | Phase 2 | 44 |
Other Products from Celltrion
Azathioprine + PlaceboApproved
85
Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)Approved
85
Infliximab + Infliximab + InfliximabApproved
85
Pioglitazone + Alogliptin + Alogliptin + Metformin + DapagliflozinApproved
85
Pioglitazone 15 MG [Actos] + Empagliflozin 10 MG [Jardiance] + Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]Approved
85